These questions are clinically relevant as anti-PD-1 and anti-CTLA-4 antibodies, used alone or in combination, are the second-line treatment option for BRAFV600 patients with melanoma resistant to targeted therapies [79]. This evidence concerns the gene CTLA4 and melanoma.